TCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid Tumors

Rhea-AI Summary

TCR² Therapeutics Inc. (Nasdaq: TCRR) announced a conference call scheduled for September 28, 2022, at 8:00 AM E.T., where details of the Phase 1 portion of its gavo-cel Phase 1/2 clinical trial for mesothelin-expressing solid tumors will be discussed. The call can be accessed via registration, and a replay will be available for 30 days on the company’s website. TCR² is focused on developing innovative T cell therapies targeting solid tumors using its proprietary TRuC platform.

CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that the Company plans to discuss the complete Phase 1 portion of the gavo-cel Phase 1/2 clinical trial for mesothelin-expressing solid tumors in a premarket press release and conference call to be held on Wednesday, September 28th, 2022 at 8:00am E.T.

In order to participate in the conference call, please register at https://bit.ly/3BTJ9Z7. Participants can register via this link up to ten minutes prior to start time. The webcast and presentation will be made available on the TCR² Therapeutics website in the Investors section under Events at investors.tcr2.com/events. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.

About TCR² Therapeutics

TCR² Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors. The company is focused on the discovery and development of product candidates against novel and complex targets utilizing its proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC^®-T cells). The TRuC platform is designed to specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). For more information about TCR², please visit www.tcr2.com.

Investor and Media Contact:
Carl Mauch
Senior Director, Investor Relations and Corporate Communications
(617) 949-5667
carl.mauch@tcr2.com

FAQ

What is the purpose of TCRR's gavo-cel Phase 1/2 clinical trial?

The gavo-cel Phase 1/2 clinical trial aims to evaluate the effectiveness of TCRR's novel T cell therapy targeting mesothelin-expressing solid tumors.

When is TCRR's conference call to discuss the clinical trial results?

The conference call to discuss the complete Phase 1 results of the gavo-cel clinical trial is scheduled for September 28, 2022, at 8:00 AM E.T.

How can I participate in TCRR's conference call?

To participate in TCRR's conference call, you need to register via the provided link up to ten minutes before the start time.

Where can I find the replay of TCRR's conference call?

The replay of TCRR's conference call will be available on the company's website for approximately 30 days after the live event.

What technology does TCRR use for its T cell therapies?

TCRR utilizes its proprietary T cell receptor Fusion Construct T cells (TRuC^®-T cells) technology to specifically target and eliminate cancer cells.